In addition to the primary findings of CANTOS where IL-1β repression resulted in a reduction in cardiovascular morbidity and mortality, residual inflammation after treatment with canakinumab (assessed through IL-6 and IL-18 tertiles) also associated with incident cardiovascular diseases (206). The gene discussed is IL1B; the disease is cardiovascular disorder.